Elevance Health Total Cost of Revenue decreased by 1.1% to $5.46B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.6%, from $4.98B to $5.46B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 18.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.61B | $2.90B | $3.07B | $2.88B | $3.07B | $3.44B | $3.65B | $3.48B | $4.33B | $4.65B | $4.84B | $3.83B | $4.82B | $5.09B | $6.01B | $4.98B | $5.29B | $5.38B | $5.52B | $5.46B |
| QoQ Change | — | +10.9% | +5.9% | -6.1% | +6.5% | +12.0% | +6.1% | -4.5% | +24.3% | +7.4% | +4.1% | -20.9% | +26.0% | +5.7% | +18.0% | -17.1% | +6.2% | +1.6% | +2.6% | -1.1% |
| YoY Change | — | — | — | — | +17.4% | +18.6% | +18.8% | +20.7% | +41.0% | +35.2% | +32.7% | +9.9% | +11.4% | +9.6% | +24.3% | +30.3% | +9.8% | +5.6% | -8.2% | +9.6% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| CarelonRx | $9.28B | $9.88B | $10.21B | $10.70B | $9.83B |
| Carelon Services | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Corporate & Other | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Health Benefits | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total | $4.98B | $5.29B | $5.38B | $5.52B | $5.46B |